NSABP P-1 TRIAL

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer is the most common malignancy affecting women in the US, and the second leading cause of cancer death. We have participated in several National Surgical Adjuvant Breast Project (NSABP) studies. These multi-institutional investigations have examined both prevention (Tamoxifen P-1 Trial) and treatment of breast cancer. The early results of this prevention study demonstrated a decrease in the incidence of breast cancer of 45% in the group of patients who received tamoxifen. The study results were reported, but not yet published. All participants were informed and are still being followed. The NSABP has not decided how many years these patients will be followed.